{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:39:08Z","timestamp":1787510348426,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"NIH National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","award":["TL1TR0003169"],"award-info":[{"award-number":["TL1TR0003169"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"NIH National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","award":["TL1TR0003169"],"award-info":[{"award-number":["TL1TR0003169"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"NIH National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","award":["TL1TR0003169"],"award-info":[{"award-number":["TL1TR0003169"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Career Enhancement Program award from the MD Anderson SPORE in Melanoma","award":["NIH\/NCI P50CA221703"],"award-info":[{"award-number":["NIH\/NCI P50CA221703"]}]},{"name":"Career Enhancement Program award from the MD Anderson SPORE in Melanoma","award":["NIH\/NCI P50CA221703"],"award-info":[{"award-number":["NIH\/NCI P50CA221703"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16889-3","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:34:09Z","timestamp":1759397649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade"],"prefix":"10.1038","volume":"15","author":[{"given":"Renato A.","family":"Guerrieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob R.","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara G.","family":"Knighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora A.","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney W.","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimmy F.","family":"Delcid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianghua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Y. B.","family":"Onana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C. L.","family":"Carapeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Tezlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Huse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella C.","family":"Glitza Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherise D.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"issue":"6","key":"16889_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ijc.30147","volume":"139","author":"KS Smalley","year":"2016","unstructured":"Smalley, K. S. et al. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int. J. Cancer. 139 (6), 1195\u20131201 (2016).","journal-title":"Int. J. Cancer"},{"issue":"6","key":"16889_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/pcmr.12538","volume":"29","author":"JV Cohen","year":"2016","unstructured":"Cohen, J. V. et al. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell. Melanoma Res. 29 (6), 627\u2013642 (2016).","journal-title":"Pigment Cell. Melanoma Res."},{"issue":"4","key":"16889_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2174\/157339411797642597","volume":"7","author":"T Leal","year":"2011","unstructured":"Leal, T. et al. Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr. Cancer Ther. Rev. 7 (4), 319\u2013327 (2011).","journal-title":"Curr. Cancer Ther. Rev."},{"issue":"Suppl 4","key":"16889_CR4","first-page":"S265","volume":"4","author":"E Le Rhun","year":"2013","unstructured":"Le Rhun, E., Taillibert, S. & Chamberlain, M. C. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg. Neurol. Int. 4 (Suppl 4), S265\u2013S288 (2013).","journal-title":"Surg. Neurol. Int."},{"issue":"9","key":"16889_CR5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.nrl.2019.10.010","volume":"37","author":"E Garcia Molina","year":"2022","unstructured":"Garcia Molina, E. & Penas-Prado, M. Neoplastic meningitis in solid tumours: updated review of diagnosis, prognosis, therapeutic management, and future directions. Neurologia (Engl Ed). 37 (9), 794\u2013805 (2022).","journal-title":"Neurologia (Engl Ed)"},{"issue":"3","key":"16889_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","volume":"142","author":"SD Ferguson","year":"2019","unstructured":"Ferguson, S. D. et al. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J. Neurooncol. 142 (3), 499\u2013509 (2019).","journal-title":"J. Neurooncol"},{"issue":"5","key":"16889_CR7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg, S. B. et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 21 (5), 655\u2013663 (2020).","journal-title":"Lancet Oncol."},{"issue":"5","key":"16889_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long, G. V. et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 19 (5), 672\u2013681 (2018).","journal-title":"Lancet Oncol."},{"issue":"11","key":"16889_CR9","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/neuonc\/noab094","volume":"23","author":"HA Tawbi","year":"2021","unstructured":"Tawbi, H. A. et al. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol. 23 (11), 1961\u20131973 (2021).","journal-title":"Neuro Oncol."},{"issue":"1","key":"16889_CR10","doi-asserted-by":"publisher","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","volume":"3","author":"IC Glitza","year":"2018","unstructured":"Glitza, I. C. et al. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 3 (1), e000283 (2018).","journal-title":"ESMO Open."},{"key":"16889_CR11","doi-asserted-by":"crossref","unstructured":"Glitza Oliva, I. C. et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat. Med., (2023).","DOI":"10.1038\/s41591-022-02170-x"},{"key":"16889_CR12","volume-title":"ESMO Congress 2023","author":"IC Glitza","year":"2023","unstructured":"Glitza, I. C. et al. M. Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD). in ESMO Congress 2023. Madrid, Spain: Annals of Oncology. (2023)."},{"issue":"2","key":"16889_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/A:1006237917632","volume":"42","author":"JC Reijneveld","year":"1999","unstructured":"Reijneveld, J. C., Taphoorn, M. J. & Voest, E. E. A simple mouse model for leptomeningeal metastases and repeated intrathecal therapy. J. Neurooncol. 42 (2), 137\u2013142 (1999).","journal-title":"J. Neurooncol"},{"issue":"6","key":"16889_CR14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","volume":"168","author":"A Boire","year":"2017","unstructured":"Boire, A. et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168 (6), 1101\u20131113e13 (2017).","journal-title":"Cell"},{"key":"16889_CR15","doi-asserted-by":"publisher","first-page":"577727","DOI":"10.1016\/j.jneuroim.2021.577727","volume":"361","author":"J Remsik","year":"2021","unstructured":"Remsik, J. et al. Characterization, isolation, and in vitro culture of leptomeningeal fibroblasts. J. Neuroimmunol. 361, 577727 (2021).","journal-title":"J. Neuroimmunol."},{"key":"16889_CR16","doi-asserted-by":"crossref","unstructured":"Remsik, J. et al. Leptomeningeal anti-tumor immunity follows unique signaling principles. BioRxiv, (2023).","DOI":"10.1101\/2023.03.17.533041"},{"key":"16889_CR17","doi-asserted-by":"crossref","unstructured":"Feoktistova, M. et al. Crystal Violet assay for determining viability of cultured cells. Cold Spring Harb Protoc., (4): (2016). pdb.prot087379","DOI":"10.1101\/pdb.prot087379"},{"issue":"22","key":"16889_CR18","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-10-0712","volume":"16","author":"W Peng","year":"2010","unstructured":"Peng, W. et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 16 (22), 5458\u20135468 (2010).","journal-title":"Clin. Cancer Res."},{"key":"16889_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejca.2021.02.016","volume":"148","author":"E Chorti","year":"2021","unstructured":"Chorti, E. et al. Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities. Eur. J. Cancer. 148, 395\u2013404 (2021).","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"16889_CR20","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.3390\/curroncol30060442","volume":"30","author":"A Nguyen","year":"2023","unstructured":"Nguyen, A. et al. Leptomeningeal metastasis: A review of the pathophysiology, diagnostic methodology, and therapeutic landscape. Curr. Oncol. 30 (6), 5906\u20135931 (2023).","journal-title":"Curr. Oncol."},{"issue":"10","key":"16889_CR21","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/neuonc\/noac054","volume":"24","author":"V Law","year":"2022","unstructured":"Law, V. et al. A preclinical model of patient-derived cerebrospinal fluid Circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neuro Oncol. 24 (10), 1673\u20131686 (2022).","journal-title":"Neuro Oncol."},{"issue":"8","key":"16889_CR22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/neuonc\/nos135","volume":"14","author":"PC Huszthy","year":"2012","unstructured":"Huszthy, P. C. et al. Vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol. 14 (8), 979\u2013993 (2012).","journal-title":"Neuro Oncol."},{"issue":"2","key":"16889_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. Loss of PTEN promotes resistance to T Cell-Mediated immunotherapy. Cancer Discov. 6 (2), 202\u2013216 (2016).","journal-title":"Cancer Discov"},{"issue":"7","key":"16889_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","volume":"2","author":"ZA Cooper","year":"2014","unstructured":"Cooper, Z. A. et al. Response to BRAF Inhibition in melanoma is enhanced when combined with immune checkpoint Blockade. Cancer Immunol. Res. 2 (7), 643\u2013654 (2014).","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"16889_CR25","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/pcmr.12498","volume":"29","author":"K Meeth","year":"2016","unstructured":"Meeth, K. et al. The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell. Melanoma Res. 29 (5), 590\u2013597 (2016).","journal-title":"Pigment Cell. Melanoma Res."},{"issue":"3","key":"16889_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/pcmr.12220","volume":"27","author":"MH Jenkins","year":"2014","unstructured":"Jenkins, M. H. et al. Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell. Melanoma Res. 27 (3), 495\u2013501 (2014).","journal-title":"Pigment Cell. Melanoma Res."},{"issue":"7","key":"16889_CR27","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"N Cancer Genome Atlas","year":"2015","unstructured":"Cancer Genome Atlas, N. Genomic classification of cutaneous melanoma. Cell 161 (7), 1681\u20131696 (2015).","journal-title":"Cell"},{"issue":"5","key":"16889_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2144\/000112598","volume":"43","author":"P Hughes","year":"2007","unstructured":"Hughes, P. et al. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? Biotechniques 43 (5), 575\u2013577 (2007).","journal-title":"Biotechniques"},{"issue":"7","key":"16889_CR29","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41590-019-0416-z","volume":"20","author":"TM Allen","year":"2019","unstructured":"Allen, T. M. et al. Humanized immune system mouse models: progress, challenges and opportunities. Nat. Immunol. 20 (7), 770\u2013774 (2019).","journal-title":"Nat. Immunol."},{"issue":"2","key":"16889_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3001","volume":"11","author":"G Francia","year":"2011","unstructured":"Francia, G. et al. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer. 11 (2), 135\u2013141 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"16889_CR31","doi-asserted-by":"publisher","first-page":"p187","DOI":"10.1146\/annurev-pathol-052016-100332","volume":"12","author":"NC Walsh","year":"2017","unstructured":"Walsh, N. C. et al. Humanized mouse models of clinical disease. Annu. Rev. Pathol. 12, p187\u2013215 (2017).","journal-title":"Annu. Rev. Pathol."},{"issue":"20","key":"16889_CR32","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1158\/0008-5472.CAN-20-0291","volume":"80","author":"M Valiente","year":"2020","unstructured":"Valiente, M. et al. Brain metastasis cell lines panel: A public resource of organotropic cell lines. Cancer Res. 80 (20), 4314\u20134323 (2020).","journal-title":"Cancer Res."},{"issue":"2","key":"16889_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1600-0625.2009.00986.x","volume":"19","author":"JC Becker","year":"2010","unstructured":"Becker, J. C. et al. Mouse models for melanoma: a personal perspective. Exp. Dermatol. 19 (2), 157\u2013164 (2010).","journal-title":"Exp. Dermatol."},{"key":"16889_CR34","doi-asserted-by":"crossref","unstructured":"Lo, J. A. et al. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med, 13(581). (2021).","DOI":"10.1126\/scitranslmed.abd8636"},{"issue":"5","key":"16889_CR35","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/jnci\/57.5.1199","volume":"57","author":"IJ Fidler","year":"1976","unstructured":"Fidler, I. J. & Nicolson, G. L. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 57 (5), 1199\u20131202 (1976).","journal-title":"J. Natl. Cancer Inst."},{"key":"16889_CR36","doi-asserted-by":"crossref","unstructured":"Overwijk, W. W. & Restifo, N. P. B16 as a mouse model for human melanoma. Curr Protoc Immunol, 2001. Chapter 20: p. Unit 20 1.","DOI":"10.1002\/0471142735.im2001s39"},{"issue":"61","key":"16889_CR37","doi-asserted-by":"publisher","first-page":"31797","DOI":"10.18632\/oncotarget.25737","volume":"9","author":"B Ben Baruch","year":"2018","unstructured":"Ben Baruch, B. et al. Stromal CD38 regulates outgrowth of primary melanoma and generation of spontaneous metastasis. Oncotarget 9 (61), 31797\u201331811 (2018).","journal-title":"Oncotarget"},{"issue":"20","key":"16889_CR38","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","volume":"72","author":"W Peng","year":"2012","unstructured":"Peng, W. et al. PD-1 Blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 72 (20), 5209\u20135218 (2012).","journal-title":"Cancer Res."},{"issue":"1","key":"16889_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-022-04118-0","volume":"160","author":"P Palmisciano","year":"2022","unstructured":"Palmisciano, P. et al. Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials. J. Neurooncol. 160 (1), 79\u2013100 (2022).","journal-title":"J. Neurooncol"},{"issue":"3","key":"16889_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ana.410270307","volume":"27","author":"MS Freedman","year":"1990","unstructured":"Freedman, M. S. et al. Immunoregulatory properties of T-cell lines derived from the systemic and intrathecal compartments: a phenotypic and functional study. Ann. Neurol. 27 (3), 258\u2013265 (1990).","journal-title":"Ann. Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16889-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16889-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16889-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:34:11Z","timestamp":1759397651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16889-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16889"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16889-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors agree with publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The Institutional Animal Care and Use Committee at MD Anderson Cancer Center approved all procedures involving mice in this study (Davies Protocol 00000743-RN02).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"34352"}}